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BACKGROUND: Endometriosis is defined as an inflamma-
tory condition of the female reproductive tract, a state
often  associated  with  infertility  and  miscarriage.
Many exogenously administered factors (treatments)
control  the  disease  via  as  yet  unknown  pathways.
Possible candidate molecules involved in these mech-
anisms could be the serum-soluble human leukocyte
antigens (sHLA) that have been detected in a variety of
human  body  fluids  and  that  are  associated  with
several diseases.
Aims: We here examine how danazol and leuprorelin
acetate  depot  treatments  exert  their  anti-inflamma-
tory  action.  It  is  plausible  that  subtle  alterations
mediated by these treatments and in relation to sHLA
may  explain  the  pathophysiology  of  endometriosis
and  provide  insights  towards  new  therapeutic
protocols.
Methods: Indirect  enzyme-linked  immunosorbent
assay (ELISA), using specific monoclonal antibodies,
determined  serum-soluble  class-I  and  class-II  HLA
levels.  ELISA  readings  from  treated  women  were
compared with normal healthy subjects.
Results: Serum-soluble class-I and class-II HLA levels
are  statistically  significantly  lower  (P <  0.001)  in
women  with  endometriosis  than  in  the  control
groups. However, danazol but not leuprorelin acetate
depot  administration  augments  soluble  HLA  class  I
and class II (P < 0.01 and P < 0.001, respectively) to
normal  levels  during  the  treatment  period,  an
increase that may account for the anti-inflammatory
effect and the remission observed.
Conlusions: It  is  shown that  one  of  the  underlying
causes  of  endometriosis  may  be  the  lack  of  both
circulating class-I and class-II antigen levels. Danazol
administration  acts  via  an  induced release of  these
antigens, whose presence correlates with the degree
of  the  inflammatory  alleviation  obtained.  We  thus
provide evidence that the inflammatory state of the
disease  appears  to  be  associated  with  soluble  HLA
levels  because, 3  months after  ceasing  therapy,  the
circulating antigens in the serum return to the same
levels that correspond to the pathological condition.
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Introduction
Endometriosis has been well  described and known
for over 50 years. However, our current knowledge of
the pathogenesis, pathophysiology of related infertil-
ity and spontaneous evolution remains unclear.
One theory for the development of endometriosis
suggests  an aberrant immune system as a causative
factor. Studies have demonstrated that women with
endometriosis  have  altered  cell-mediated  immu-
nity,1–3 which could allow translocated endometrial
cells  to  implant  and  progress. Additionally,  women
with endometriosis have also been shown to exhibit
an altered humoral immunity4–6 as well as increased
macrophage  numbers  and  their  activation,7 events
that lead to a severe local inflammatory state.
Surface human leukocyte antigen (HLA) genotypes
have  been  associated with  more  than  30  diseases,
including  systemic lupus  erythomatosus, ankylosing
spondylitis, and multiple sclerosis. The etiology and
pathogenesis of many of these, mainly autoimmune,
disorders  are  unknown.  Susceptibility  to  diseases
associated with surface HLA is likely to be determined
by multiple genes as well as environmental factors.8
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an autoimmune basis underlying this particular malady
led  investigators  to  evaluate  the  HLA  genotype  in
endometriosis.9,10 Moen et al.10 studied surface HLA in
100 women with endometriosis where no association
between HLA and the disease was found.
Recently,  however,  it has been shown that intra-
cellular pools of HLA, residing in cytoplasmic orga-
nelles, may be released to the extracellular matrix as
soluble  particles,  and  may  enter  the  circulation
following  stimulation  by  various  endogenous  or
exogenous factors.11 Serum-soluble (circulating) HLA
antigens  have  also  been  detected  in  a  variety  of
human  body  fluids  and  associated  with  several
diseases (reviewed in Ref. 12). Candidate stimuli may
be considered a wide array of factors that have been
reviewed  by  Ho  et  al.13 and  comprise  known
inflammatory cytokines, including interferon-g (IFN-
g ) and tumor necrosis factor-a (TNF-a ), characterized
by their ability to induce surface histocompatibility
antigens. Since endometriosis is defined as an inflam-
matory  condition of  the  female  reproductive  tract,
and occurrence of  both IFN-g and TNF-a has been
documented  in  this  particular  state,13 we  inquired
whether  secreted/soluble  HLA  class-I  and  class-II
antigens are present in the serum of endometriotic
patients. We  also investigated the  effect of danazol
and leuprorelin acetate depot on the levels of these
antigens, and correlated the findings to their pharma-
ceutical anti-inflammatory action.
Materials and methods
Patients
The  study  population  included  68  women  with
infertility that attended the Department of Obstetrics
and Gynecology of the University Hospital of Crete
from  1991  to  1999.  All  the  women  underwent
laparoscopic examination because of suspected endo-
metriosis. The  University  Committee approved spe-
cific  and  future  protocols,  and  written  informed
consent  was  obtained  from  each  subject  before
participation, all in accordance with the Declaration
of Helsinki. Sera of the women, who accepted to be
part of  the research projects, have been previously
used  for  the  detection  of  other  immunologic  vari-
ables5,6 as  well  as  prolactin,  thyroid  stimulating
hormone and soluble CD23.14,15
Thirty-eight  of  the  women  had  endometriosis
(mean, 27.7 ± 5.8 years) and 30 had no pelvic disease
(mean,  29.2  ±  5.7  years). After  their  case histories
were  compiled,  clinical  examinations  were  carried
out; their husbands’ semen was normal in all cases.
Thereafter,  ovulation  was  tested,  cervical  mucus
evaluated, and tubal potency ascertained by hystero-
salpingography.  All  examinations  showed  normal
results for all women.
According to the classification issued by the Amer-
ican Fertility Society,16 subjects were classified into
two groups: 30 with pelvic pain who had no disease
on laparoscopy were considered as controls, and 38
women with laparoscopically diagnosed and staged
endometriosis (15 cases) were at stage I, 11 at stage II,
six at stage III, and six at stage IV. Due to the diversity
of  the  aforementioned  endometriotic  stages,  the
patients underwent different extents of surgery. No
residues of endometriotic tissue  could  be  detected
macroscopically  after  completion  of  surgery.  This
observation assures that our results  are free of any
possible bias that would jeopardize the interpretation
of the results that follow. The study was open-labeled
and the women with endometriosis were assigned to
the two groups (danazol and leuprorelin).
The first 11 women were given danazol capsules,
an  isoxazolic  derivative  of  synthetic  steroid,
17a-ethynyletestosterone, 200mg by mouth every 8h
for  6  months. The  stage  of  endometriosis  of  this
specific group of study was in favor of stage I since
five out of the 11 patients were in this category. The
group also consisted of two women in each of the II,
III and IV stages.
The second group of 11 women was treated with
leuprorelin acetate depot, 3.75mg every 28 days for 6
months. This set contained three patients in stage I,
four  in  stage II,  and two in  each of  the III and IV
stages.
Finally,  the  distribution  stage  of  endometriotic
women who did not receive treatment (16 patients)
was seven in stage I, five in II, and two in each of the
III and IV stages. Blood samples were taken from all
women  before  laparoscopy  for  the  evaluation  of
soluble HLA class-I and class-II levels.
Serum-soluble HLA levels were also measured in the
22  endometriotic women, before treatment, during
the last 15 days of a 6-month course of danazol and
leuprorelin  acetate,  and  3  months  after  treatment.
Blood samples from women with endometriosis were
collected between the fifth and seventh day of their
menstrual  cycle  before  and  after  treatment. Within
1h, blood samples were centrifuged at 3000rpm (400
´ g) and serum was kept at –80°C until assayed.
Reagents
Serum-soluble HLA (class I and class II) levels were
determined  by  indirect  enzyme-linked  immunosor-
bent assay (ELISA)17,18 (see next section), using the
monoclonal antibodies 83H1 (HLA-A,B,C; IgG1) and
7H3 (HLA-DR; IgG2a), respectively.19,20
Enzyme-linked immunoassay (ELISA)
The ELISA experiments were performed as previously
described.17,18 First,  in  order  to  ensure  linearity
between  antigen  concentration  (sera)  and  optical
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various dilutions (1:10, 1:50, 1:100, 1:500 and 1:100)
and chose the appropriate one. Briefly, sera collected
as already mentioned were used at a concentration of
1:100 in carbonate buffer (pH 9.6). These were coated
in  96-well  flat bottom plates (Sarstedt, Numbrecht,
Germany),  incubated  overnight  at 4°C  and  washed
four  times  in  5% Tween-20  (Sigma,  St.  Louis,  MO,
USA). The remaining  protein free sites in  the plate
were blocked by 2% phosphate-buffered saline-bovine
serum albumen (PBS-BSA) solution after an incubation
of 2h at room temperature. After washing four times,
100 m l  test  antibody  diluted  in  0.1%  PBS-BSA  were
added and  incubated  for  1h  at  room  temperature.
Extensive  washing  of  the  plate  was  followed  by
addition  of  100 m l  goat  anti-rabbit  IgG  coupled  to
horseradish peroxidase (1:1000 dilution; Sigma) and
incubated for 1h at room temperature, in the dark.
Finally,  the  reaction  was  developed  by  adding
100 m l/well  tetramethyl  benzidine-H2O2 (Sigma)  for
20min. The  enzymatic  reaction  was  stopped  with
50 m l H2SO4 (4N). OD was measured at 450nm using
a Titertec ELISA photometer (Digiscan; ASYS Hitech
GmbH, Engendorf, Austria). All samples from each of
the women were measured in the same run and the
results  were  expressed  as  the  percent  of  optical
density increase over background, i.e. test’s internal
control (±SEM).
Statistical analysis
The  paired  Student  t-test  was  used  for  statistical
evaluation. For statistical analysis, we used an inde-
pendent t-test for among-group comparisons, and the
paired t-test for within-group comparisons, and the
Pearson  correlation  coefficient  for  correlation
analysis.
Results
The percent of serum-soluble HLA class-I and class-II
levels  in  women  without  endometriosis  (controls)
and those with endometriosis are presented in Figure
1. As this figure shows, soluble HLA (sHLA) class-I and
class-II  levels  (percent  of  OD  increase  over  back-
ground)  were  statistically  significantly  lower  (P <
0.001) in women with endometriosis than in control
subjects.
All 22 patients developed amenorrhea during the
danazol and leuprorelin acetate depot treatments. The
before-treatment menstrual cycles of women studied
were normal. As expected, pain related to endome-
triosis  was  gradually  alleviated  and  menses  dis-
appeared  in  all  22  women  during  treatment. After
cessation of treatment, menstrual bleeding returned
to normal in 1–2 months. The percent of modulation
of the serum-soluble HLA class I in the women with
endometriosis  before,  during  and  3  months  after
treatment with danazol or  leuprorelin,  respectively,
are presented in  Figure  2. As shown in  this figure,
sHLA  class-I  levels  were  statistically  significantly
higher  (P <  0.01)  during  danazol  treatment  than
before treatment. On the contrary, leuprorelin acetate
depot administration had no effect on the levels of
sHLA class I (Fig. 2). Three months after ceasing the
treatments, sHLA class I returned to almost the same
level as before treatment (Fig. 2).
Figure  3  provides  the  serum  levels  expressed  as
percent  of  OD  increase  over  background  (mean  ±
SEM) of the sHLA class II in women with endome-
Serum-soluble HLA levels in endometriosis
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FIG. 1. Serum-soluble human leukocyte antigen (sHLA) class-I and class-II levels in healthy subjects (controls, white bars) and
in  women with endometriosis (black  bars).  Soluble class  I  was detected by the monoclonal antibody 83H1  (HLA-A,B,C,
IgG1),
19,20 and class II by the monoclonal antibody 7H3 (HLA-DR, IgG2a).
20 The decrease of soluble antigens for both HLA
classes is of the significance order of P < 0.001. The results are expressed as percent of optical density (OD) increase over
background levels (±SEM). Background levels (OD values of coating buffer) corresponded to 0.110 ± 0.015 and 0.075 ± 0.008
for  the  class-I  and  class-II  antibodies,  respectively. The  experiment  was  repeated  three  times  and  similar  results  were
obtained.triosis before, during and 3 months after treatment
with danazol or leuprorelin, respectively. As shown in
this  figure,  sHLA  class-II  levels  were  statistically
significantly  higher  (P <  0.001)  during  danazol
treatment than before treatment. In contrast, leupror-
elin  administration did  not change significantly  the
levels of  sHLA  class II  (Fig.  3). Three  months after
abandoning treatments, sHLA class-II levels reverted
to  those  before  treatment  (Fig.  3).  Finally,  it  is
underlined that a correlation was not found between
sHLA class I and class II and the severity (stage) of
endometriosis.
Discussion
Several population and family studies have disclosed
an association between certain diseases and a partic-
ular  surface  HLA  phenotype.  These  diseases  fre-
quently manifest immunologic disorders. Population
studies yield statistically strong evidence in support of
an association between a disease susceptibility gene
and  a  given  HLA  antigen/epitope.  Through  family
studies, on the contrary, investigators can determine
whether a linkage exists between HLA and a disease
susceptibility gene.
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FIG. 2. Serum-soluble human leukocyte antigen (sHLA) class-I levels in women with endometriosis before, during and after
treatment with danazol (black bars) or leuprorelin acetate depot (white bars), respectively. For the antibody employed for class
I, see Figure 1. The increase obtained in response to danazol during the actual treatment time is of the order of P < 0.01. The
results are expressed as the percent of optical density (OD) increase over background levels (±SEM). Background levels (OD
values of coating buffer) for the class-I antibody corresponded to 0.110 ± 0.015. The experiment was repeated three times and
similar results were obtained.
FIG. 3. Serum-soluble human leukocyte antigen (sHLA) class-II levels in women with endometriosis before, during and after
treatment with danazol (black bars) or leuprorelin acetate depot (white bars), respectively. For the antibody employed for class
II, see Figure 1. The increase obtained in response to danazol during the actual treatment time is of the order of P < 0.001. The
results are expressed as the percent of optical density (OD) increase over background levels (±SEM). Background levels (OD
values of coating buffer) for the class-II antibody corresponded to 0.075 ± 0.008. The experiment was repeated three times and
similar results were obtained.Endometriosis  shows  these  characteristics. Simp-
son et al.21 demonstrated an increased incidence and
severity of endometriosis in first-degree relatives of
probands with endometriosis. Epidemiologic studies
have also shown a familial tendency and an increased
concordance  of  endometriosis  in  twins.22–25
Although these findings are consistent with inherit-
ance of this disease as a polygenic/multifactorial trait,
etiologic factors causing endometriosis remain largely
unknown.
Surface  HLA  expression,  an  event  under  genetic
control, and endometriosis appear to be independent
findings since Moen et al.10 has demonstrated that
there  is  no  correlation  between  these  two  para-
meters. There are, however, intracellular stores con-
taining HLA antigens that await a stimulus in order to
be  expressed  on  the  surface  and  released  in  the
extracellular  matrix.  These  soluble/circulating  HLA
forms have been discovered in numerous body fluids,
yet their significance remains speculative.12
Active secretion of HLA class I and class II by liver
cells and activated immunocompetent cells has made
these secreted forms be considered as normal con-
stituents of the serum.12,26 In a recent study, the levels
of  the  serum-soluble  forms  of  class-I  and  class-II
antigens have been established during normal preg-
nancy  and  first  trimester  abortions,27 and  their
presence  has been  correlated to  a successful  preg-
nancy outcome since they can be used as predictive
markers. This  observation  renders  the  production/
presence of these molecules in the serum attractive
candidates for the delineation of infertility in general.
If one thus considers that sHLA-DR (class II)  levels
appear to be relatively high during normal pregnancy
and, according to the present communication, sHLA
class-II levels are lower than normal during endome-
triosis, it may be claimed that endometriosis-caused
infertility  is  associated  with  the  levels  of  serum-
soluble HLA class-II antigens. By the same token, the
extremely low levels of sHLA class I detected in first
trimester abortions27 and their suppression in endo-
metriotic  women  may  imply  that  absence  of  this
secreted molecule(s) is also involved in the pathways
of infertility.
In  the  present  study,  we  found  that  circulating
HLA  class-I  and  class-II  levels  are  low  in  infertile
women  with  endometriosis  compared  with  con-
trols.  To  date,  no  data  are  available  concerning
sHLA  class-I  and  class-II  levels  during  treatment
with  danazol  and  leuprorelin  acetate  depot  in
women  with  endometriosis.  It  is  surprising  that
danazol but not leuprorelin administration increased
significantly  the  levels  of  both  soluble  class  I  and
class II (P < 0.01 and P < 0.001, respectively). This
difference,  however,  shows  the  dissimilar  mode  of
action  of  the  two  therapies  and  may  underlie  the
fact  that,  pharmacologically,  leuprorelin  is  less
potent than danazol.
Three  months  after  withdrawing  the  danazol  or
leuprorelin  acetate  depot  treatments,  the  levels  of
sHLA class I and class II returned to almost the same
as those before administration (Figs. 2 and 3). These
results  strongly  indicate  involvement  of  soluble/
circulating  HLA  antigens  in  the  development  and
maintenance of ectopic endometrial cells.
The mechanism(s) by which an HLA antigen loses its
ability  to  be  anchored  in  the  cell  membrane  and
becomes  released  has  recently  gained  grounds  of
evidence.11There is increasing support, however, that
the  serum-soluble  HLA  forms  play  a  role  in  the
pathophysiology of many diseases that, to date, had no
genetic link with specific surface HLA epitopes.28This
view renders the study of many maladies a complicated
task to undertake since the regulatory mechanisms
that govern such transition(s) will engage a number of
new parameters that will delay the delineation of the
pathways involved. In our laboratory, we are currently
investigating  how  the  circulating  human  leukocyte
antigens affect endometriosis, and are attempting to
determine the optimal levels to which an organism
may be tolerant and thus unaffected by their presence
so as to prevent the ailment.
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